EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score

Timothy T Pham, Aliza S Gordon, Xiaoxue Chen, David Debono, Michael J Fisch

Cancer Treatment and Research Communications · 2023

DOI: 10.1016/j.ctarc.2023.100769 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Timothy T Pham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Elevance Health, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Little is known about the effectiveness of immunotherapy alone or with chemotherapy for patients with non-small cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) expression

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsHumansB7-H1 AntigenImmunotherapyCarboplatin

Stichwörter der Autor:innen

Clinical outcomesHealthcare costHealthcare utilizationNon-small cell lung cancerPD-L1

Substanzen

B7-H1 AntigenAntineoplastic Agents, ImmunologicalNK 121Carboplatin

Autor:innen und Institutionen

  • Elevance Health, Indianapolis, IN, United States.
  • Elevance Health, Indianapolis, IN, United States. Electronic address: Aliza.gordon@elevancehealth.com.
  • Carelon Medical Benefits Management, Chicago, IL, United States.

Zitieren

APA

Pham, T. T., Gordon, A. S., Chen, X., Debono, D., & Fisch, M. J. (2023). Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100769

Vancouver

Pham TT, Gordon AS, Chen X, Debono D, Fisch MJ. Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score. Cancer Treatment and Research Communications. 2023. doi:10.1016/j.ctarc.2023.100769

BibTeX
@article{Pham2023,
  author = {Pham, Timothy T and Gordon, Aliza S and Chen, Xiaoxue and Debono, David and Fisch, Michael J},
  title = {Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score},
  journal = {Cancer Treatment and Research Communications},
  year = {2023},
  doi = {10.1016/j.ctarc.2023.100769}
}
Kostenlos starten →